Released Nov 2, 2023, after the close
10-Q filed Nov 6, 2023, 37 days after period end · 0001636422-23-000133
Q3 2023 · 10-Q
Revenue$73.77M$73.77M +7.9% vs Q3 2022+0.8% vs Q2 2023
Net Income-$22.03M-$22.03M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.39-$0.39 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$24,580,000N/M
Operating Cash Flowderived$3,115,000N/M
Free Cash Flowderived$2,966,000N/M
Margins · derived
Operating margin-33.3%+33.6 pt vs Q3 2022
Net margin-29.9%+37.0 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $73.77M | $68.35M | $61.74M | $47.19M |
| Net Income | -$22.03M | -$45.74M | -$40.01M | -$27.33M |
| EPS Diluted | -$0.39 | -$0.84 | -$0.82 | -$0.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR